Myeloproliferative neoplasms, including polycythaemia vera, essential thrombocythaemia, and myelofibrosis, are driven by clonal haematopoietic expansion, frequently harbouring JAK2, CALR, or MPL mutations. JAK1/2 inhibitors including ruxolitinib, fedratinib, and pacritinib have transformed the management of myelofibrosis. Disease modification, reduction of transformation risk, and improving overall survival remain unmet goals.
Iron Status Clarifies Erythrocytosis, Symptoms in Polycythemia Vera
New insights from EHA 2026 clarify the role of iron status in erythrocytosis and symptom burden in polycythemia vera patients.
JAK Inhibitor Combinations Show Efficacy in Myelofibrosis at EHA 2026
New data from EHA 2026 indicate that combination therapies involving JAK inhibitors may improve outcomes for myelofibrosis patients.
Avapritinib Improves Outcomes in Nonadvanced and Advanced Systemic Mastocytosis
New data from the Summit and Apex trials demonstrate avapritinib's efficacy in systemic mastocytosis, offering a targeted treatment option.